EDAP EDAP TMS SA

EDAP TMS Follows Up on the Success of HIFU With Ablatherm at Recent International Congresses VAULX-EN-VELIN, France, Oct. 7 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP), a global leader in the development, marketing and distribution of a portfolio of minimally-invasive medical devices for the treatment of urological diseases, today follows up on its recent participation in two major international congresses in Japan and Germany. The 4th International Society for Therapeutic Ultrasound (ISTU) held in Kyoto, Japan, on September 18-20, 2004 was a great success. The growing interest for HIFU technology applied to the medical field reinforces the need for such International Society whose objectives are to encourage research on therapeutic ultrasound and promote international scientific and industrial cooperation. Many presentations were made on the use of therapeutic ultrasound to treat various tumors from kidney tumors to breast's, heart's, liver's, prostate's, etc ... The ISTU Symposium confirmed the leadership of Ablatherm as the first and most advanced approved product using High Intensity Focused therapeutic Ultrasound to treat localized prostate cancer. Dr. Gelet, from Edouard Herriot hospital, Lyon, France, presented his successful clinical results over 10 years using HIFU with Ablatherm and Dr. Thuroff, from Harlaching Hospital, Munich, Germany, shared his long experience of HIFU technology. Our Research Partner, INSERM, also presented its development programs, still experimental, on the application of therapeutic ultrasound to kidney tumors. Mr. Hugues de Bantel, Chief Executive Officer of EDAP TMS, commented: "We can really observe the growing interest from the Scientific and Medical communities for this technology. Therapeutic ultrasound opens a new era of minimally-invasive treatments addressing various cancer indications at a lower medical cost." EDAP also participated in the 56th Congress of the German Society for Urology (D.G.U.: Deutsche Gesellschaft fur Urologie) held in Wiesbaden, Germany, on September 22-25, 2004. More than 3,000 Urologists attended the Congress where EDAP's "Meet the Experts" workshop achieved a real success. Ablatherm users were all very keen on sharing openly their HIFU experience with doctors coming to enquire about HIFU with Ablatherm applied to localized prostate tumors. Judith Johannsen, General Manager of EDAP Germany, commented: "We are very enthusiastic about this growing interest for HIFU in Germany. We can tell that HIFU with Ablatherm made a real breakthrough at this year's DGU, which was confirmed by a larger number of Urologists coming to get information about this new treatment. Many of these physicians have had a positive feedback from their patients treated with HIFU and were enquiring about sharing an Ablatherm on a mobile basis." Mr. Hugues de Bantel, Chief Executive Officer of EDAP TMS, concluded: "We see a clear progress of our Ablatherm business in the third largest single market after the U.S.A. and Japan and we look forward to reporting to you about this breakthrough during our Third Quarter conference call, to be held on October 28, 2004." EDAP TMS will also be participating in two upcoming congresses: - The "World Congress of Endourology" (W.C.E.) on November 3-6, 2004 to be held in Mumbai, India (booths # 113 & 114), - The "Association Francaise d'Urologie" (A.F.U.) on November 17-20, 2004 to be held in Paris, France (booth # F40). EDAP TMS S.A. is the global leader in the development, production, marketing and distribution of a portfolio of minimally invasive medical devices primarily for the treatment of urological diseases. The Company currently develops and markets devices for the minimally invasive treatment of localized prostate cancer, using High Intensity Focused Ultrasound (HIFU), through its EDAP SA subsidiary; it is also developing this technology for the treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL), via its TMS SA subsidiary. In addition, the Company markets in Japan and Italy devices for the non-surgical treatment of benign Prostate Hyperplasia (BPH) using Microwave Thermotherapy (TUMT). For more information, contact the Investor Relations Department by phone at +33 (0)4 78 26 40 46. For additional information on the Company, please see the Company's web site at: http://www.edap-tms.com/. This press release contains, in addition to historical information, forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. CONTACT: Hugues de Bantel - Philippe Chauveau - Blandine Confort +33 4 78 26 40 46 DATASOURCE: EDAP TMS S.A. CONTACT: Hugues de Bantel, Philippe Chauveau or Blandine Confort, all of EDAP TMS S.A., +33-4-78-26-40-46 Web site: http://www.edap-tms.com/

Copyright